open access

Vol 13, No 5 (2017)
Guidelines / Expert consensus
Get Citation

Soft tissue sarcomas in adults

Redakcja: Piotr Rutkowski, Iwona Ługowska
DOI: 10.5603/OCP.2017.0025
·
Oncol Clin Pract 2017;13(5):181-201.

open access

Vol 13, No 5 (2017)
GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Soft tissue sarcomas in adults

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 5 (2017)

Article type

Guidelines / Expert consensus

Pages

181-201

DOI

10.5603/OCP.2017.0025

Bibliographic record

Oncol Clin Pract 2017;13(5):181-201.

Authors

Redakcja: Piotr Rutkowski
Iwona Ługowska

References (55)
  1. Rutkowski P. (ed.) Mięsaki tkanek miękkich. Via Medica, Gdańsk 2015.
  2. Wojciechowska U, Didkowska J. Nowotwory w Polsce w 2012 roku. Nowotwory. Journal of Oncology. 2013; 63(3): 197–216.
  3. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: iii102–iii112.
  4. Fletcher CDM, Bridge JA, Hogendoorn PCW. WHO Classification of tumours of soft tissue and bone. Lyon: IARC. 2013.
  5. Lasota J. Molecular genetics in soft tissue tumors. In: Miettinen M. ed. Modern soft tissue pathology. Tumors and non-neoplastic conditions. University Press, Cambridge 2010: 127–180.
  6. Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC. ed. AJCC Cancer Staging Manual. Springer, New York 2010: 291–296.
  7. Amin MB, Edge S, Greene FA. Cancer Staging Manual, 8th edition. Springer International Publishing, Cham 2017.
  8. Bonvalot S, Miceli R, Berselli M, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010; 17(6): 1507–1514.
  9. Gronchi A, Miceli R, Colombo C, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol. 2012; 23(4): 1067–1073.
  10. Alektiar K. Soft-Tissue Sarcoma. Clinical Radiation Oncology. 2016: 1345–1372.e4.
  11. Rossi CR, Vecchiato A, Mastrangelo G, et al. Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). Ann Oncol. 2013; 24(6): 1685–1691.
  12. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982; 196(3): 305–315.
  13. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998; 16(1): 197–203.
  14. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996; 14(3): 859–868.
  15. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002; 359(9325): 2235–2241.
  16. Koseła-Paterczyk H, Szacht M, Morysiński T, et al. Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas. Eur J Surg Oncol. 2014; 40(12): 1641–1647.
  17. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113(3): 573–581.
  18. Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012; 30(8): 850–856.
  19. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017; 18(6): 812–822.
  20. Issels RD, Lindner LH, Verweij J, et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG), European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010; 11(6): 561–570.
  21. Trabulsi NH, Patakfalvi L, Nassif MO, et al. Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials. J Surg Oncol. 2012; 106(8): 921–928.
  22. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11(7): 1276–1285.
  23. Judson I, Verweij J, Gelderblom H, et al. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15(4): 415–423.
  24. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007; 25(19): 2755–2763.
  25. Demetri GD, von Mehren M, Jones RL. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase iii randomized multicenter clinical trial. J Clin Oncol. 2016; 34(8): 786–793.
  26. van der Graaf WTA, Blay JY, Chawla SP, et al. EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379(9829): 1879–1886.
  27. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group, Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010; 28(10): 1772–1779.
  28. Blay JY, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014; 50(6): 1137–1147.
  29. Cesne ALe, Blay JY, Cupissol D, et al. Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS). Annals of Oncology. 2016; 27(suppl_6).
  30. Le Cesne A, Blay JY, Domont J, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol. 2015; 16(3): 312–319.
  31. Demetri GD, Schöffski P, Grignani G, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016; 387(10028): 1629–1637.
  32. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016; 388(10043): 488–497.
  33. Gounder MM, Stacchiotti S, Schöffski P, et al. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). J Clin Oncol. J Clin Oncol. 2017; Suppl(abstract 11058).
  34. Voutsadakis IA, Zaman K, Leyvraz S. Breast sarcomas: current and future perspectives. Breast. 2011; 20(3): 199–204.
  35. Bousquet G, Confavreux C, Magné N, et al. Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol. 2007; 85(3): 355–361.
  36. Rutkowski P, Śpiewankiewicz B, Koseła H, et al. Sarcoma of the uterus: diagnostic and therapeutic recommendations. Current Gynecologic Oncology. 2013; 11(1): 24–32.
  37. McMeekin DS. Sarcoma of the uterus. In: DiSaia P, Creasman W. ed. Clinical gynecologic oncology. Eight edition Elsevier 2013: 175–188.
  38. Reed NS, Mangioni C, Malmström H, et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008; 44(6): 808–818.
  39. Gronchi A, Colombo C, Pechoux CLe, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. Annals of Oncology. 2013; 25(3): 578–583.
  40. Kasper B, Baumgarten C, Bonvalot S, et al. Desmoid Working Group. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise - a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015; 51(2): 127–136.
  41. Rutkowski P, Lugowska I. Follow-up in soft tissue sarcomas. Memo. 2014; 7(2): 92–96.
  42. Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438(1): 1–12.
  43. ESMO/European Sarcoma Network Working Group, ESMO / European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7: vii49–vii55.
  44. Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013; 20(9): 2937–2943.
  45. Rutkowski P, Wozniak A, Dębiec-Rychter M, et al. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer. 2011; 117(21): 4916–4924.
  46. Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007; 14(7): 2018–2027.
  47. Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol. 2016; 34(3): 244–250.
  48. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26(4): 620–625.
  49. Heinrich MC, Rankin C, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7): 472–480.
  50. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23): 4342–4349.
  51. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544): 1329–1338.
  52. Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015; 121(9): 1405–1413.
  53. Demetri GD, Reichardt P, Kang YK, et al. GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 295–302.
  54. Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer. 2013; 49(5): 1027–1031.
  55. Bauer S, Rutkowski P, Hohenberger P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib ― analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014; 40(4): 412–419.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl